Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency

Sep 05 2025

• By Bridget Silverman

Making complete response letters public for unapproved products is a big leap for the FDA's radical transparency initiative. (Shutterstock)

Related Content

Real-Time Release Of CRLs Is US FDA’s Goal, Agency Leaders Affirm

Jul 25 2025

US FDA’s CRL Release More Incremental Than ‘Radical’ Transparency

Jul 10 2025

US FDA Emphasizes Primary Endpoint Primacy In Vatiquinone, Lytenava CRLs

Sep 03 2025

US FDA Advisory Committee Conduct Could Take Center Stage in Lykos Appeal of MDMA Rejection

Aug 12 2024

Complete Response Letter Trio Raises Prospect Of Tidal Shift In Regenerative Medicine Regulation

Jul 23 2025

US FDA Teases Disclosure Program, But Industry Has Seen This Before

Jun 13 2025

Related Companies

SFJ Pharmaceuticals, Inc

Immedica Pharma AB

Atara Biotherapeutics, Inc.

Pierre Fabre

Milestone Pharmaceuticals, Inc.

Aldeyra Therapeutics, Inc.

Stealth BioTherapeutics Inc.

Xspray Pharma AB

MEDRx Co., Ltd.

PTC Therapeutics, Inc.

Lykos Therapeutics

Replimune Group Inc.

Capricor Therapeutics, Inc.

Ultragenyx Pharmaceutical Inc.

Additional Topics

More from Complete Response Letters

More from Complete Response Letters

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window